Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Richard Lussier, Stephen Quake

Premium

CLC Bio has appointed Richard Lussier as director of business in the Americas region. He joins CLC Bio from RainDance Technologies, where he was vice president of worldwide sales. He has also held positions at Solexa (now Illumina), Fluidigm, Applied Biosystems (now Life Technologies), and Celera Genomics (now Quest Diagnostics).


Stephen Quake has won the $500,000 Lemelson-MIT prize for outstanding innovators for his work in drug discovery, genome analysis, and personalized medicine

Quake has co-founded a number of companies based on technology he has developed in his lab, including Fluidigm, Quantical Pharmaceuticals, and ImmuMetrix. He also helped develop the single-molecule sequencing technology that was commercialized by Helicos BioSciences, and the fetal DNA sequencing techniques commercialized by Verinata Health.

He is a professor of bioengineering and applied physics at Stanford University. He holds a BS and MS in mathematics from Stanford and a PhD in physics from the University of Oxford.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.